Triple-negative breast carcinoma Trials in Duarte, United States
Conditions / Triple-negative breast carcinoma / Duarte, United States
Research into Triple-negative breast carcinoma spans multiple therapeutic approaches and trial phases.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01349959 | Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer | COMPLETED | PHASE2 |
| NCT00861705 | Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery | COMPLETED | PHASE2 |
| NCT02120469 | Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer | COMPLETED | PHASE1 |
| NCT03012100 | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT02996825 | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | COMPLETED | PHASE1 |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT07136493 | Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer | SUSPENDED | NA |
| NCT00892736 | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | COMPLETED | PHASE1 |
| NCT02954874 | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT02648477 | Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer | COMPLETED | PHASE2 |